Article Text

Download PDFPDF
Attitudes towards termination of pregnancy in subjects who underwent presymptomatic testing for theBRCA1/BRCA2 gene mutation in The Netherlands
  1. L N LODDER*,
  2. P G FRETS*,
  5. J G M KLIJN,
  1. *Department of Medical Psychology and Psychotherapy, Erasmus University Rotterdam/Netherlands Institute for Health Sciences, PO Box 1738, 3000 DR Rotterdam, The Netherlands
  2. †Department of Clinical Genetics, University Hospital Dijkzigt/Erasmus University Rotterdam, Rotterdam, The Netherlands
  3. ‡Department of Medical Oncology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
  1. Dr Lodder, L.N.Lodder{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Editor—The identification of theBRCA1 and BRCA2gene mutations in 1994 and 1995 respectively1 2 allowed detection of mutation carriers in families with autosomal dominant hereditary breast/ovarian cancer. Female mutation carriers have a risk of 56-87% of developing breast cancer and of 10-60% for ovarian cancer.3 The options are either frequent surveillance or prophylactic surgery. For male mutation carriers, cancer risks are only slightly increased. The offspring of mutation carriers have a 50% chance of inheriting the gene mutation. The possibility of prenatal genetic diagnosis for “late onset diseases”, such as hereditary breast/ovarian cancer, raises complex ethical questions.4 5 The present study addresses the question to what extent physicians and policy makers working in genetics or oncology may expect requests for prenatal diagnosis and termination of pregnancy because of carriership forBRCA1/BRCA2.

A questionnaire assessing attitudes towards termination of pregnancy if the fetus …

View Full Text